Parent Project Muscular Dystrophy Provides $500,000 in Funding to Kinea Bio Through PPMD Venture Pathways Program to Support Next-Gen Midi-Dystrophin Gene Therapy Development
WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.
- WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.
- The organization prioritizes research for next-generation and future-generation gene therapies both through PPMD's Gene Therapy Initiative and the PPMD Venture Pathways program.
- Casey Childers, DO, PhD, Chief Executive Officer of Kinea Bio, explains:
"We are pleased to receive this funding commitment from PPMD. - In addition to PPMD's significant pre-clinical and academic research funding, the organization provides funding to biopharmaceutical companies through PPMD Venture Pathways, its venture philanthropy program.